Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients

Inclusion Criteria: 1. Histological and immunohistochemistry (IHC) confirmed recurrent or metastatic triple-negative breast cancer . 2. Previous chemotherapy should include anthracycline or taxane; No prior chemotherapy after metastasis. 3. Females with age between 18 and 70 years old 4. ECOG performance status 0 or 1. 5. At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST) by magnetic resonance imaging, or computed tomography; The target lesions is Unresectable; The target lesions did not receive radiotherapy or relapse within the radiation field; 6. Life expectancy ≥ 12 weeks.； 7. WBC count ≥ 4 × 109 / L, neutrophils ≥ 1.5 × 109 / L, platelet count ≥ 100 × 109 / L, hemoglobin ≥ 6.21mmol / L (10 g / dL); 8. Total bilirubin (TBL)≤ 1.5 x ULN (upper limit of normal reference values); AST and ALT ≤ 2.5 x ULN or ≤ 5 ULN (Liver metastasis);Serum creatinine ≤ 1.5 x ULN. 9. Before enrollment, patients have fully recovered from previous treatment-related toxicity; 10. Subjects with fertility must accept effective contraceptive measures; 11. Signed informed consent Exclusion Criteria: 1. Previously treatment regimen including anti EGFR monoclonal antibody; 2. Receiving other anti-cancer medicine treatment during the study 3. Participate in other clinical trials within 4 weeks in this group; 4. Accepted taxane treatment in 1 year; 5. Presence of neurological symptoms due to brain metastasis, patients receiving steroidal anti-edema drugs therapy; 6. Patients having a history of clinically significant symptomatic angina, arrhythmia or congestive heart failure without control; 7. Diagnosed with severe interstitial pneumonitis or pulmonary fibrosis by chest CT; 8. Pleural effusion, ascites require to be drained; 9. Adverse drug addiction and drug abuse, long-term alcoholics, as well as AIDS patients; patients with severe or uncontrolled complications, such as infection requiring systemic therapy, fever (≥ 38 ℃), diabetes or hypertension can not be controlled by medicine, other complications may interfere with drug therapy; 10. Patients with a history of drug allergy (≥ CTCAE 2 level) such as shock or allergic symptoms, especially have allergic reactions to similar drugs in the past, have severe allergies reactions to drugs containing polysorbate eighty (Tween 80); 11. Uncontrolled seizures or loss of insight due to mental disorders; 12. Pregnant or lactating women； 13. Researchers think improper for this trial